Salvage chemotherapy in relapsed germ cell tumors

2001 ◽  
Vol 19 (2) ◽  
pp. 90-93 ◽  
Author(s):  
J. Beyer ◽  
O. Rick ◽  
W. Siegert ◽  
C. Bokemeyer
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy

scholarly journals GCT-28. RECURRENCE PATTERN AND SURVIVAL FOR RELAPSED INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS: A SINGLE-INSTITUTION EXPERIENCE

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii333-iii333
Author(s):  
Lei Wen ◽  
Zhaoming Zhou ◽  
Qingjun Hu ◽  
Juan Li ◽  
Mingyao Lai ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Late Recurrence ◽  
Salvage Chemotherapy ◽  
Recurrence Time ◽  
First Line ◽  
Primary Tumor Site ◽  
First Line Therapy ◽  
Line Therapy

Abstract PURPOSE Intracranial non-germinomatous germ cell tumors (NGGCTs) have lower overall survival than germinoma because relatively higher recurrence usually occurs after first line therapy. METHODS Between January 2003 and December 2018, 111 consecutive patients diagnosed with NGGCTs reviewed. Those who progressed after first line therapy were included in this study. Data of first line treatment, salvage treatment, clinicopathological features and survival were collected and analyzed. RESULTS Totally, thirty patients (30/111, 27.0%) relapsed in our cohort, including 19 patients with accurate relapse information detail, and 11 patients who died of disease progression during follow up but without exact time and site of relapse. The median OS from diagnosis of the disease was 49.2 months (95% CI: 14.1 to 84.3 months) and 3-year OS was 54.3%. Patients who received both CSI and chemotherapy relapsed less than those who received reduced volume of radiotherapy or only CSI or only chemotherapy (22.5% vs. 45.5%, p=0.034). Of 19 patients who had detail information of recurrence time and site, the median time from diagnosis of disease to relapse was 9.5 months (2.2 to 72.1 months). Regarding to recurrence site, most patients relapsed in primary site (10/19, 52.6%) or distant intracranial (6/19, 31.6%). The recurrence site of other 3 patients were spinal (n=1), ventricular (n=1) and peritoneal (n=1). CONCLUSION Protracted follow-up is recommended because late recurrence is not uncommon. Primary tumor site and distant intracranial are the most prevalent relapsed location. Patients who relapsed could benefited from both CSI and salvage chemotherapy.

2599 Gemcitabine, Cisplatin, and Paclitaxel (GCT) as second-line salvage chemotherapy for germ cell tumors

2015 ◽  
Vol 51 ◽  
pp. S511
Author(s):  
A. Carus ◽  
J. Lauritsen ◽  
M. Agerbæk ◽  
H. Von der Maase ◽  
G. Daugaard
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy ◽  
Second Line

scholarly journals A Study of Patients with Primary Mediastinal Germ Cell Tumors Treated Using Multimodal Therapy

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Yutaro Tanaka ◽  
Takehiko Okamura ◽  
Takashi Nagai ◽  
Daichi Kobayashi ◽  
Takahiro Kobayashi ◽  
...  
Keyword(s):  
Germ Cell ◽  
Multimodal Treatment ◽  
Lung Metastases ◽  
Germ Cell Tumors ◽  
Residual Tumor ◽  
Salvage Chemotherapy ◽  
Yolk Sac Tumors ◽  
Node Metastases ◽  
Mediastinal Germ Cell Tumors ◽  
Observation Period

Objectives. Primary mediastinal germ cell tumors (PMGCTs) are rare, which often makes them difficult to treat. Herein, we examined patients with PMGCTs who underwent multimodal treatment.Methods. We examined 6 patients (median age: 25 years, range: 19–27 years) with PMGCTs who underwent multimodal treatment between April 2001 and March 2015. Three patients had seminomas, 2 patients had yolk sac tumors, and 1 patient had choriocarcinoma. The median observation period was 32.5 months (range: 8–84 months).Results. Three of the 6 patients received initial operation followed by 3-4 courses of chemotherapy (bleomycin, etoposide, and cisplatin (BEP) or etoposide and cisplatin (EP)). One patient developed multiple lung metastases 17 months after surgery; received salvage chemotherapy with vinblastine, ifosfamide, and cisplatin; and achieved complete remission. The remaining 3 patients received initial BEP and EP chemotherapy. Multiple lung metastases and supraclavicular lymph node metastases were detected in 2 of these patients at the initial diagnosis. The patients underwent resections to remove residual tumor after treatment, and no viable tumor cells were found.Conclusions. Reliable diagnosis and immediate multimodal treatments are necessary for patients with PMGCTs. The 6 patients treated in our hospital have never experienced recurrence after the multimodal treatment.

Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors

Onkologie ◽  
2011 ◽  
Vol 34 (8) ◽  
pp. 416-420 ◽  
Author(s):  
Silvia Park ◽  
Soohyeon Lee ◽  
Jeeyun Lee ◽  
Se Hoon Park ◽  
Joon Oh Park ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy

UP-03.111 TIN Therapy as Salvage Chemotherapy for Cisplatin Refractory Germ Cell Tumors

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S379-S380
Author(s):  
T. Nakamura ◽  
K. Mikami ◽  
Y. Kimura ◽  
F. Hongo ◽  
N. Takaha ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy

4536 POSTER Salvage chemotherapy in patients with recurrent germ cell tumors (GCT)

2007 ◽  
Vol 5 (4) ◽  
pp. 309
Author(s):  
M. Foldyna ◽  
J. Abrahámová ◽  
J. Nepomucká ◽  
Z. Donátová ◽  
E. Vorilková ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumors ◽  
Salvage Chemotherapy

Malignant germ cell tumors of the ovary: 20-year report of LAC-USC Women's Hospital

1994 ◽  
Vol 4 (1) ◽  
pp. 29-35 ◽  
Author(s):  
J. P. Curtin ◽  
C. P. Morrow ◽  
G. D'Ablaing ◽  
J. B. Schlaerth
Keyword(s):  
Germ Cell ◽  
Combination Chemotherapy ◽  
Postoperative Radiotherapy ◽  
Germ Cell Tumors ◽  
Reproductive Function ◽  
Salvage Chemotherapy ◽  
Surgical Staging ◽  
Second Look ◽  
Initial Surgery ◽  
Malignant Germ Cell Tumors

Thirty-six patients with malignant germ cell tumors (GCT) of the ovary were treated during the period from 1971 to 1990. Twenty-five of these patients underwent initial surgery at this institution; 11 were referred after initial surgery. Endodermal sinus tumor (EST) was the most common subtype (N= 13), followed by immature teratoma (IMT)N= 11), dysgerminoma (N= 9), and mixed germ cell tumor (N= 3). Eight of nine patients with dysgerminoma and 14 of 27 patients with non-dysgerminomatous germ cell tumors had stage I disease. Surgical staging resulted in a change of stage in 10 of 31 patients; seven were upstaged, and three were downstaged. Thirty-five of 36 patients are alive with no evidence of disease at a median follow-up of 47 months (range 12–210 months). Two of nine patients with dysgerminoma received postoperative radiotherapy; two additional patients required radiotherapy for recurrence. Twenty-five of 27 patients with non-dysgerminomatous tumors were treated with combination chemotherapy. Second-look laparotomy was done in 18 patients, four of whom had positive results. Three of the four patients with positive second-look laparotomy results remain free of disease after salvage chemotherapy; the fourth patient died of progressive grade 3 IMT. Nineteen of 27 patients undergoing fertility-preserving surgery have resumed normal menses, and four of these have delivered normal infants. The other eight patients remain on oral contraceptives. We conclude that surgical staging provided important information in this study of 36 patients with ovarian germ cell malignancies. As noted by many previous reports, combination chemotherapy (developed during the past 20 years) has dramatically improved prognosis for this group of patients. Second-look laparotomy (SLL), especially for patients with advanced disease, was able to identify patients requiring additional therapy. Most patients with this disease can retain their normal, uninvolved ovary with preservation of normal menstrual and reproductive function.

Sign in / Sign up

Export Citation Format

Share Document